Fortis Healthcare Limited Tower-A, Unitech Business Park ......Tower-A, Unitech Business Park,...
2
FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel : 0124 492 1033 Fax : 0124 492 1041 Emergency : 105010 Email : [email protected] Website : www.fortishealthcare.com FHL/SEC/STEX/RR/2018-19 April 5, 2018 The National Stock Exchange of India Ltd. Corporate Communications Department “Exchange Plaza”, 5th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai – 400051 Scrip Symbol: FORTIS BSE Limited Corporate Services Department Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001 Scrip Code:532843 Sub: Update Dear Sirs, We would like to inform that Daiichi Sankyo Company Limited (“Daiichi”) had filed an application in the pending petition before the Hon’ble High Court of Delhi on April 4, 2018. Fortis Healthcare Limited (“the Company”) is not a party in the said petition. However. Daiichi in the said application has inter-alia prayed for ‘maintaining status quo of the assets of the Company and such other related matters’, thereby seeking injunction on the scheme of arrangement for demerger of the hospital business of the Company into Manipal Health Enterprises Private Limited (“Manipal”). The said application was heard today. We would like to inform that neither any interim nor any adverse order has been passed in the hearing today. Considering the reliefs prayed for in the said application, Court has ordered that the Company be impleaded as a party therein and has granted it opportunity to file counter affidavit to the application. Further, the Board of Directors had approved the de-merger of its hospitals business with Manipal on March 27, 2018. In the outcome of the said meeting, it was informed that the merger is subject to shareholders’ approval, creditors’ approval and applicable regulatory approvals (including Competition Commission of India, SEBI, Stock Exchanges and the National Company Law Tribunal). The detailed disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith as Annexure A. We will keep the stock exchanges informed about any further updates in this regard. This is for your kind information and records purposes. Thanking you, Yours Faithfully For Fortis Healthcare Limited Rahul Ranjan Company Secretary ACS17035
Transcript of Fortis Healthcare Limited Tower-A, Unitech Business Park ......Tower-A, Unitech Business Park,...
FORTIS HEALTHCARE LIMITED
Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062
Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933
Fortis Healthcare Limited
Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)
Tel : 0124 492 1033
Fax : 0124 492 1041
Emergency : 105010
Email : [email protected]
Website : www.fortishealthcare.com
FHL/SEC/STEX/RR/2018-19 April 5, 2018
The National Stock Exchange of India Ltd. Corporate Communications Department “Exchange Plaza”, 5th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai – 400051 Scrip Symbol: FORTIS
BSE Limited Corporate Services Department Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001 Scrip Code:532843
Sub: Update
Dear Sirs,
We would like to inform that Daiichi Sankyo Company Limited (“Daiichi”) had filed an application in the pending petition before the Hon’ble High Court of Delhi on April 4, 2018. Fortis Healthcare Limited (“the Company”) is not a party in the said petition. However. Daiichi in the said application has inter-alia prayed for ‘maintaining status quo of the assets of the Company and such other related matters’, thereby seeking injunction on the scheme of arrangement for demerger of the hospital business of the Company into Manipal Health Enterprises Private Limited (“Manipal”). The said application was heard today.
We would like to inform that neither any interim nor any adverse order has been passed in the hearing today. Considering the reliefs prayed for in the said application, Court has ordered that the Company be impleaded as a party therein and has granted it opportunity to file counter affidavit to the application.
Further, the Board of Directors had approved the de-merger of its hospitals business with Manipal on March 27, 2018. In the outcome of the said meeting, it was informed that the merger is subject to shareholders’ approval, creditors’ approval and applicable regulatory approvals (including Competition Commission of India, SEBI, Stock Exchanges and the National Company Law Tribunal).
The detailed disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith as Annexure A. We will keep the stock exchanges informed about any further updates in this regard.
This is for your kind information and records purposes.
Thanking you,
Yours Faithfully For Fortis Healthcare Limited Rahul Ranjan Company Secretary ACS17035
FORTIS HEALTHCARE LIMITED
Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062
Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933
Fortis Healthcare Limited
Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)
Tel : 0124 492 1033
Fax : 0124 492 1041
Emergency : 105010
Email : [email protected]
Website : www.fortishealthcare.com
Annexure A Disclosures as required under Regulation 30
of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
S. No Particulars Description
1 Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation
Name(s) of Opposing Party- Daiichi Sankyo Company Limited Court- High Court of Delhi Details of Dispute/litigation- Daiichi has filed an application in the pending Execution Petition praying for the following reliefs against the Respondents in the main execution petition where the Company is not a party:
• Direct the Respondents to fulfill the undertaking as recorded in order dated 21.6.2017, prior to effectuating any scheme of restructuring/transaction involving FHL;
• Direct status quo to be maintained as regards the assets of FHL;
• In an alternative, direct the Respondents to deposit the entire Award amount along with interest and costs prior to concluding any scheme of restructuring / transaction involving FHL;
• Order the appearance of Respondent No. 1 (Mr. Malvinder Mohan Singh), Respondent No. 4 (Mrs. Japna Malvinder Singh), Respondent No. 6 (Mr. Shivinder Mohan Singh), Respondent No.8 (Mrs. Aditi Shivinder Singh) and Respondent No.13 (Mrs. Nimmi Singh) in the event of failure of Respondent to comply with abovementioned Prayers;
• Restrain the Respondent No. 1 (Mr. Malvinder Mohan Singh), Respondent No.4 (Mrs. Japna Malvinder Singh), Respondent No.6 (Mr. Shivinder Mohan Singh), Respondent No. 8 (Mrs. Aditi Shivinder Singh) and Respondent No.13 (Mrs. Nimmi Singh) from leaving India without the leave of Court.
2 Expected financial implications, if any, due to compensation, penalty etc.
No expected financial implications
3 Quantum of claims, if any
None
